Discovery of Novel Indazole Chemotypes as Isoform-Selective JNK3 Inhibitors for the Treatment of Parkinson's Disease.
Sign Up to like & getrecommendations! Published in 2023 at "Journal of medicinal chemistry"
DOI: 10.1021/acs.jmedchem.2c01410
Abstract: c-Jun N-terminal kinases (JNKs) are involved in the pathogenesis of various diseases. In particular, JNK3 and not JNK1/2 is primarily expressed in the brain and plays a key role in mediating neurodegenerative diseases like Parkinson's… read more here.
Keywords: isoform selective; jnk3; parkinson disease; jnk3 inhibitors ... See more keywords
Thiophene-Pyrazolourea Derivatives as Potent, Orally Bioavailable, and Isoform-Selective JNK3 Inhibitors
Sign Up to like & getrecommendations! Published in 2021 at "ACS Medicinal Chemistry Letters"
DOI: 10.1021/acsmedchemlett.0c00533
Abstract: Potent JNK3 isoform selective inhibitors were developed from a thiophenyl-pyrazolourea scaffold. Through structure activity relationship (SAR) studies utilizing enzymatic and cell-based assays, and in vitro and in vivo drug metabolism and pharmacokinetic (DMPK) studies, potent… read more here.
Keywords: orally bioavailable; jnk3 inhibitors; selective jnk3; jnk3 ... See more keywords